Clinical Endoscopy

The Korean Society of Gastrointestinal Endoscopy (대한소화기내시경학회)
권호 표지
DOI QR코드

DOI QR Code

Small Bowel Endoscopic Bariatric Therapies

  • Gong, Eun Jeong (Department of Internal Medicine, Gangneung Asan Hospital) ;
  • Kim, Do Hoon (Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center)
  • Received : 2018.09.02
  • Accepted : 2018.09.19
  • Published : 2018.09.30
⟨ Previous Next ⟩

Abstract

Endoscopic bariatric therapies that emulate some of the principles of bariatric surgery have been developed as a less invasive option for the treatment of obesity and related comorbidities. Small bowel endoscopic bariatric therapies include bypass sleeves, incisionless anastomosis systems, and duodenal mucosal resurfacing. Clinical experience with small bowel devices suggests that endoscopic bariatric procedures can be safely implemented and that these devices are effective for both weight loss and metabolic improvement. Although the mechanisms behind these effects should be further elucidated, endoscopic bariatric therapies may be more effective and safer adjunctive interventions than lifestyle modifications and pharmacological regimens for patients with obesity or obesity-related comorbidities.

Keywords

References

  1. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006;355:763-778. https://doi.org/10.1056/NEJMoa055643
  2. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006;244:741-749. https://doi.org/10.1097/01.sla.0000224726.61448.1b
  3. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 2017;376:641-651. https://doi.org/10.1056/NEJMoa1600869
  4. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015;386:964-973. https://doi.org/10.1016/S0140-6736(15)00075-6
  5. Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology 2017;152:1791-1801. https://doi.org/10.1053/j.gastro.2017.01.044
  6. Jirapinyo P, Thompson CC. Endoscopic bariatric and metabolic therapies: surgical analogues and mechanisms of action. Clin Gastroenterol Hepatol 2017;15:619-630. https://doi.org/10.1016/j.cgh.2016.10.021
  7. Machytka E, Buzga M, Zonca P, et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes. Gastrointest Endosc 2017;86:904-912. https://doi.org/10.1016/j.gie.2017.07.009
  8. Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002;236:554-559. https://doi.org/10.1097/00000658-200211000-00003
  9. Pories WJ, Albrecht RJ. Etiology of type II diabetes mellitus: role of the foregut. World J Surg 2001;25:527-531. https://doi.org/10.1007/s002680020348
  10. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Rouxen-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004;240:236-242. https://doi.org/10.1097/01.sla.0000133117.12646.48
  11. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004;89:2608-2615. https://doi.org/10.1210/jc.2004-0433
  12. Mason EE. The mechanisms of surgical treatment of type 2 diabetes. Obes Surg 2005;15:459-461. https://doi.org/10.1381/0960892053723330
  13. Patriti A, Facchiano E, Sanna A, Gulla N, Donini A. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 2004;14:840-848. https://doi.org/10.1381/0960892041590818
  14. Mason EE. Ileal [correction of ilial] transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Obes Surg 1999;9:223-228. https://doi.org/10.1381/096089299765553070
  15. Maljaars PW, Peters HP, Mela DJ, Masclee AA. Ileal brake: a sensible food target for appetite control. A review. Physiol Behav 2008;95:271-281. https://doi.org/10.1016/j.physbeh.2008.07.018
  16. Cohen R, le Roux CW, Papamargaritis D, et al. Role of proximal gut exclusion from food on glucose homeostasis in patients with type 2 diabetes. Diabet Med 2013;30:1482-1486. https://doi.org/10.1111/dme.12268
  17. Dixon JB, le Roux CW, Rubino F, Zimmet P. Bariatric surgery for type 2 diabetes. Lancet 2012;379:2300-2311. https://doi.org/10.1016/S0140-6736(12)60401-2
  18. Meek CL, Lewis HB, Reimann F, Gribble FM, Park AJ. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 2016;77:28-37. https://doi.org/10.1016/j.peptides.2015.08.013
  19. Jirapinyo P, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care 2018;41:1106-1115. https://doi.org/10.2337/dc17-1985
  20. Rodriguez L, Reyes E, Fagalde P, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther 2009;11:725-732. https://doi.org/10.1089/dia.2009.0063
  21. Tarnoff M, Rodriguez L, Escalona A, et al. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc 2009;23:650-656. https://doi.org/10.1007/s00464-008-0125-4
  22. Gersin KS, Rothstein RI, Rosenthal RJ, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc 2010;71:976-982. https://doi.org/10.1016/j.gie.2009.11.051
  23. Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg 2010;251:236-243. https://doi.org/10.1097/SLA.0b013e3181bdfbff
  24. Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg 2014;260:984-992. https://doi.org/10.1097/SLA.0000000000000794
  25. ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, Abu Dayyeh BK, Kumar N, et al. ASGE bariatric endoscopy task force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015;82:425-438.e5. https://doi.org/10.1016/j.gie.2015.03.1964
  26. Rohde U, Hedback N, Gluud LL, Vilsboll T, Knop FK. Effect of the EndoBarrier gastrointestinal liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2016;18:300-305. https://doi.org/10.1111/dom.12603
  27. Betzel B, Koehestanie P, Homan J, et al. Changes in glycemic control and body weight after explantation of the duodenal-jejunal bypass liner. Gastrointest Endosc 2017;85:409-415. https://doi.org/10.1016/j.gie.2016.07.027
  28. Forner PM, Ramacciotti T, Farey JE, Lord RV. Safety and effectiveness of an endoscopically placed duodenal-jejunal bypass device ($EndoBarrier^{(R)}$): outcomes in 114 patients. Obes Surg 2017;27:3306-3313. https://doi.org/10.1007/s11695-017-2939-4
  29. Betzel B, Koehestanie P, Aarts EO, et al. Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity. Gastrointest Endosc 2015;82:845-852. https://doi.org/10.1016/j.gie.2015.03.1911
  30. Quezada N, Munoz R, Morelli C, et al. Safety and efficacy of the endoscopic duodenal-jejunal bypass liner prototype in severe or morbidly obese subjects implanted for up to 3 years. Surg Endosc 2018;32:260-267. https://doi.org/10.1007/s00464-017-5672-0
  31. Sandler BJ, Rumbaut R, Swain CP, et al. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc 2011;25:3028-3033. https://doi.org/10.1007/s00464-011-1665-6
  32. Sandler BJ, Rumbaut R, Swain CP, et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc 2015;29:3298-3303. https://doi.org/10.1007/s00464-015-4081-5
  33. Ryou M, Aihara H, Thompson CC. Minimally invasive entero-enteral dual-path bypass using self-assembling magnets. Surg Endosc 2016;30:4533-4538. https://doi.org/10.1007/s00464-016-4789-x
  34. Machytka E, Buzga M, Ryou M, Lautz DB, Thompson CC. Endoscopic dual-path enteral anastomosis using self-assembling magnets: first-inhuman clinical feasibility. Gastroenterology 2016;150(4 Suppl 1):S232.
  35. Rajagopalan H, Cherrington AD, Thompson CC, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care 2016;39:2254-2261. https://doi.org/10.2337/dc16-0383

Cited by

  1. Endoscopic bariatric treatments : new toolkit in the armamentarium against obesity vol.30, pp.2, 2018, https://doi.org/10.1097/mol.0000000000000585